Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation

Drug Metabolism and Disposition

Volumn 39, Issue 8, 2011, Pages 1324-1328

  Uchaipichat, Verawan ^a,b   Raungrut, Pritsana ^a,c   Chau, Nuy ^a   Janchawee, Benjamas ^c   Evans, Allan M ^d   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b KHON KAEN UNIVERSITY   (Thailand)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; KETAMINE; MORPHINE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; METABOLIC REGULATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ANALGESICS, OPIOID; ANIMALS; CELL CULTURE TECHNIQUES; CODEINE; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HEK293 CELLS; HUMANS; INSECTS; KETAMINE; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MORPHINE; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; TRANSFECTION;

BOVINAE;

EID: 79960599549     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039727     Document Type: Article

References (25)

1. Bell RF (1999) Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 83: 101-103.
2. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503. (Pubitemid 35356875)
3. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433. (Pubitemid 41428474)
4. Clements JA and Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 53:27-30. (Pubitemid 11210925)
5. Dayton PG, Stiller RL, Cook DR, and Perel JM (1983) The binding of ketamine to plasma proteins: emphasis on human plasma. Eur J Clin Pharmacol 24:825-831. (Pubitemid 13064478)
6. Fitzgibbon EJ and Viola R (2005) Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 8:49-57. (Pubitemid 40144251)
7. Hasselström J and Säwe J (1993) Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24:344-354.
8. Idvall J, Ahlgren I, Aronsen KF, and Stenberg P (1979) Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 51:1167-1173. (Pubitemid 10171522)
9. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486. (Pubitemid 38519653)
10. Jin CJ, Mackenzie PI, and Miners JO (1997) The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 341:207-211. (Pubitemid 27203023)
11. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132. (Pubitemid 40386722)
12. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461. (Pubitemid 30229449)
13. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25. (Pubitemid 38268090)
14. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
15. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
16. Qi X, Evans AM, Wang J, Miners JO, Upton RN, and Milne RW (2010) Inhibition of morphine metabolism by ketamine. Drug Metab Dispos 38:728-731.
17. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, and Miners JO (2010) In vitro-in vivo extrapolation predicts drug-drug interactions from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole and methadone in humans. J Pharmacol Exp Ther 334:609-618.
18. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062. (Pubitemid 43763765)
19. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
20. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
21. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089. (Pubitemid 37048278)
22. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423. (Pubitemid 38420275)
23. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
24. Xie H, Wang X, Liu G, and Wang G (2003) Analgesic effects and pharmacokinetics of a low dose of ketamine preoperatively administered epidurally or intravenously. Clin J Pain 19: 317-322. (Pubitemid 37075673)
25. Yue QY, Hasselström J, Svensson JO, and Säwe J (1991) Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 31:635-642.